Search Results
Showing Results for Cell therapy
At #ASCO25, key neuro-oncology presentations explored focused ultrasound to enhance drug delivery, the benefits of maximal surgical resection in IDH-mutant gliomas, and final CATNON data supporting adjuvant temozolomide. Other highlights included improved cognitive outcomes with stereotactic radiosurgery for brain metastases and early results from a novel gamma delta T cell therapy.
We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1 Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2 Head and neck squamous cell carcinoma (...
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important ...
Dr. Pooja Ghatalia, an Associate Professor at Fox Chase Cancer Center, specializes in genitourinary oncology, focusing on kidney and bladder cancers. With expertise in immunotherapy and biomarker development, she combines cutting-edge research with compassionate care. Inspired by exceptional mentors, she advocates for persistence, curiosity, and patient-centered oncology, shaping future oncologists.
Q&A with Dr Benjamin Weinberg: Understanding rare GI cancers (small bowel, appendix and anal cancer)
Rare gastrointestinal (GI) cancers present unique challenges in diagnosis, treatment and research. Dr. Benjamin Weinberg discusses three of the rarest GI cancers: small bowel, appendix and anal cancer.
“The patient always comes first – that lesson guides every decision I make” Dr Ari Rosenberg (University of Chicago Medicine, Chicago, IL, USA) specializes in the treatment of head and neck cancer, salivary gland cancer and thyroid cancer. His particular ...
The US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for zongertinib (BI 1810631), a treatment for adults with advanced non-small cell lung cancer (NSCLC) characterized by HER2 (ERBB2) mutations who have undergone prior ...
News release in anticipation of International Childhood Cancer Day 2025 Brussels, 15 February 2025 The European childhood cancer community anticipates and celebrates International Childhood Cancer Day by addressing one of the most pressing challenges in paediatric oncology: cross-border access to care and research. ...
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors ...
"While groundbreaking treatments are transformative, patients often remember the kindness and humanity of their oncologist more than the medicine they receive" Introducing our Future Leaders series, in this interview Dr Rodrigo Munhoz (Oncology Center – Hospital Sírio-Libanês in Sã...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
Oesophageal cancer is the eighth most commonly diagnosed cancer and is the sixth leading cause of cancer death worldwide.1,2 Worldwide, around 604,100 new instances of oesophageal cancer were recorded in 2020, leading to approximately 544,100 deaths. This translates to a standardized incidence rate ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
